金河生物
(002688)
| 流通市值：53.99亿 | | | 总市值：55.56亿 |
| 流通股本：7.50亿 | | | 总股本：7.72亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,390,257,781.02 | 625,145,364.48 | 2,370,626,965.11 | 1,657,273,697.64 |
| 营业收入 | 1,390,257,781.02 | 625,145,364.48 | 2,370,626,965.11 | 1,657,273,697.64 |
| 二、营业总成本 | 1,247,233,707 | 569,770,727.13 | 2,178,879,190.03 | 1,530,578,504.1 |
| 营业成本 | 909,856,811.62 | 401,461,943.22 | 1,576,257,210.52 | 1,105,938,899.22 |
| 税金及附加 | 12,384,182.76 | 5,882,721.31 | 17,602,452.63 | 12,101,915.29 |
| 销售费用 | 80,054,557.52 | 41,676,064.18 | 138,303,486.84 | 99,721,319.65 |
| 管理费用 | 154,100,617.77 | 77,746,262.18 | 285,819,440.74 | 197,806,033.33 |
| 研发费用 | 46,480,516.49 | 22,598,102.58 | 94,002,290.67 | 56,656,746.61 |
| 财务费用 | 44,357,020.84 | 20,405,633.66 | 66,894,308.63 | 58,353,590 |
| 其中:利息费用 | 45,003,056.8 | 22,075,500.85 | 80,335,510.72 | 57,420,653.68 |
| 其中:利息收入 | 1,683,177.74 | 1,128,705.2 | 6,896,094.14 | 4,704,772.3 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -35,990.75 | -28,413.75 | 45,462 | 77,664.25 |
| 加:投资收益 | -1,228,413.97 | 87,375 | -1,269,364.34 | -631,039.01 |
| 资产处置收益 | 77,451.57 | - | 194,370.44 | 13,381.3 |
| 资产减值损失(新) | 2,605,551.61 | 572,214.29 | -82,022,808.9 | -17,338,597.73 |
| 信用减值损失(新) | -153,117.08 | -260,381.07 | -40,164,106.01 | -3,572,694.97 |
| 其他收益 | 15,670,458.96 | 3,864,033.64 | 30,020,094.32 | 20,099,005.62 |
| 四、营业利润 | 159,960,014.36 | 59,609,465.46 | 98,551,422.59 | 125,342,913 |
| 加:营业外收入 | 131,496.31 | 7,428.37 | 1,565,075.41 | 325,635.63 |
| 减:营业外支出 | 463,439.75 | 12,800.96 | 2,332,732.36 | 1,457,769.99 |
| 五、利润总额 | 159,628,070.92 | 59,604,092.87 | 97,783,765.64 | 124,210,778.64 |
| 减:所得税费用 | 21,676,945.54 | 7,821,503.23 | 13,461,738.66 | 11,145,338.59 |
| 六、净利润 | 137,951,125.38 | 51,782,589.64 | 84,322,026.98 | 113,065,440.05 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 137,951,125.38 | 51,782,589.64 | 84,322,026.98 | 113,065,440.05 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 137,918,599.3 | 51,116,537.85 | 100,200,680.03 | 113,761,436.1 |
| 少数股东损益 | 32,526.08 | 666,051.79 | -15,878,653.05 | -695,996.05 |
| 扣除非经常损益后的净利润 | 128,167,962.88 | 48,941,580.13 | 83,788,691.45 | 102,546,587.71 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.18 | 0.07 | 0.13 | 0.15 |
| (二)稀释每股收益 | 0.18 | 0.07 | 0.13 | 0.15 |
| 八、其他综合收益 | -2,540,523.77 | -842,776.01 | 7,829,841.42 | -6,794,267.1 |
| 归属于母公司股东的其他综合收益 | -2,159,445.2 | -716,359.61 | 6,655,365.21 | -5,775,127.04 |
| 九、综合收益总额 | 135,410,601.61 | 50,939,813.63 | 92,151,868.4 | 106,271,172.95 |
| 归属于母公司股东的综合收益总额 | 135,759,154.1 | 50,400,178.24 | 106,856,045.24 | 107,986,309.06 |
| 归属于少数股东的综合收益总额 | -348,552.49 | 539,635.39 | -14,704,176.84 | -1,715,136.11 |
| 公告日期 | 2025-07-31 | 2025-04-26 | 2025-04-26 | 2024-10-28 |
| 审计意见(境内) | | | 标准无保留意见 | |